Sirona Biochem Publishes Corporate Update for Canadian Business Journal

VANCOUVER, British Columbia, September 28, 2022 (GLOBE NEWSWIRE) — Sirona Biochem Corporation(TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona) announces the release of a corporate update focused on the company’s recent team meeting in France, its current pipeline and its latest deal structure.

The successful licensing deal with AbbVie should prepare the company for its next phase of growth.

Dr. Wolfgang Bieber reports: ”

Full company updates can be viewed at the following links:

About Sirona Biochem Corporation

Sirona Biochem is a cosmetic ingredients and drug discovery company with proprietary platform technology. Sirona specializes in the stabilization of carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented to maximize revenue potential.

Sirona’s compounds are licensed to leading companies around the world in exchange for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, his TFChem, is located in France and has won several French national scientific awards, as well as grants from the European Union and the French government. For more information, please visit www.sironabiochem.com.

For more information about this press release, please contact:

Investor inquiry:
Jonathan Williams
Managing director
Momentum PR
Phone: 1.450.332.6939
Email: [email protected]

Neither TSX Venture Exchange nor its regulated service providers (as those terms are defined in the TSX Venture Exchange Policy) are responsible for the adequacy or accuracy of this release.

———————————————

Sirona Biochem cautions that statements contained in this press release that are not statements of historical fact may be forward-looking statements. Forward-looking statements are only predictions based on current expectations and are subject to known and unknown risks and uncertainties. These forward-looking statements speak only as of the date of release of the relevant information, unless expressly stated otherwise. Actual results, performance or achievements may differ materially from those expressed or implied in Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business. testing; difficulties or delays in product development, testing, obtaining regulatory approval, manufacturing and marketing; Unexpected adverse side effects or insufficient therapeutic efficacy of the product, which may delay or hinder the development or commercialization of the product; Scope and efficacy of product patent protection. Competition with other pharmaceutical or biotechnology companies. and the ability to raise additional funding to support its operations. Sirona Biochem undertakes no obligation to update any forward-looking statements, except as required by law.

CBJ Newsmaker